The islet of Langerhans plays a key role in glucose homeostasis through regulated secretion of the hormones insulin and glucagon. Islet research has focused on the insulin-secreting β-cells, even though aberrant glucagon secretion from α-cells also contributes to the aetiology of diabetes. Despite its importance, the mechanisms controlling glucagon secretion remain controversial.
| INTRODUCTION
The islet of Langerhans regulates glucose homeostasis through dosedependent secretion of hormones including insulin from the β-cells and glucagon from α-cells. 1 Over the physiological blood glucose range, glucagon levels track in opposition to insulin, and the subsequent actions of these 2 hormones are opposite in almost all respects. 2 During hypoglycaemia, insulin secretion is shut off, while maximal glucagon levels stimulate glucose output from the liver. As glucose increases, glucagon secretion becomes suppressed, and insulin begins to rise. 3 The 2 hormones are opposite in yet another way:
the major regulatory mechanisms underlying insulin secretion have been exquisitely characterized, while the mechanisms controlling secretion of glucagon remain controversial-even 70 years after the identification of islet α-cells as its source. 4 
"
The major regulatory mechanisms underlying insulin secretion have been exquisitely characterized, while the mechanisms controlling secretion of glucagon remain controversial.
Both insulin and glucagon are dysregulated in type 1 or type 2 diabetes. 5, 6 The therapeutic benefits of insulin in diabetes have led most research to focus on the insulin-secreting β-cells 7 even though we now know that aberrant glucagon secretion from α-cells exacerbates hyperglycaemia in diabetes. 8, 9 In particular, glucagon suppression by glucose and/or insulin becomes lost, and hyperglucagonaemia persists at all glucose levels. 10 It has even been proposed that hyperglucagonaemia, rather than insulin deficiency, is the primary driver of hyperglycaemia. 11, 12 Indeed, it has been repeatedly demonstrated that inhibition of glucagon secretion or of glucagon action during diabetes can lead to restoration of euglycaemia, even in the absence of insulin. [13] [14] [15] [16] Following these discoveries, several lines of glucagon receptor antagonists have been developed for type 2 diabetes, but early trial data showed that these agents tend to raise glucagon levels and inflict side effects on the liver, the main target organ of glucagon action. 17 A safer alternative strategy may be to directly control glucagon secretion. Recent data from our lab show that brown adipose tissue transplants can reduce glucagon levels and reverse type 1 diabetes phenotypes in mice without insulin. 18, 19 While glucagon antagonism represents the next frontier in diabetes treatment, progress towards this goal is hampered by our poor mechanistic understanding of α-cell function. 20, 21 Glucose inhibition of glucagon secretion (GIGS) is an important proof-of-concept case for understanding mechanisms that govern α-cell exocytosis. The glucose response profile of glucagon from islets is similar to that measured in vivo, 22 and similar responses are also measured from reconstituted pseudo-islet clusters containing α-, β-and δ-cells. 23 These data suggest that glucose-regulation of glucagon secretion requires only islet-intrinsic factors and does not require input from blood flow patterns or central nervous system activity.
Multiple hypotheses have been proposed to explain how glucose inhibits glucagon secretion (GIGS). The "electrophysiology model"
states that each α-cell intrinsically contains the mechanism(s) of -independent inhibitory pathway.
A second set of models for the regulation of α-cell secretion are "paracrine inhibition" models. In these models, a secretory product of transporter has no effect on GIGS from islets, [35] [36] [37] which opposes a primary role for Zn
2+
. It is likely that, especially for paracrine interactions, multiple mechanisms must work together for proper regulation of glucagon secretion.
Finally, beyond α-cell intrinsic and paracrine mechanisms, juxtacrine signalling also plays an important role in regulating glucagon secretion. While no functional evidence has been presented supporting a role for gap junctions linking α-cells to other islet cells, ephrinA to EphA4/7 forward signalling has been shown to inhibit glucagon secretion by F-actin polymerization. 38 EphA forward signalling could also interact with cAMP or Ca 2+ regulated pathways, 39 and protein kinase enzyme (PKA) activation is known to affect F-actin rearrangements. 40 Such synergistic interplay between signalling pathways will make it even more challenging to unravel the precise signalling networks that underlie glucagon secretion. Hopefully, new mechanistic understanding of glucagon secretion will be a significant step towards developing novel pharmacological strategies for treating dysglycaemia in diabetes. 
| CALCIUM IS NOT ENOUGH

| α-CELL HETEROGENEITY
Heterogeneity underlies each cell population of the islet. 54, 55 One of the main challenges in islet cell biology is to determine the biological function of such heterogeneity. A recent surge of data have demonstrated considerable heterogeneity among β-cells: they differ in connectivity, developmental origins, transcriptomes, rates of insulin synthesis and release, also propensity for death or proliferation. [56] [57] [58] [59] [60] [61] One preserved theme in β-cells, though, is that despite their heterogeneity, they exhibit remarkably synchronous and precise response to glucose-triggered Ca 2+ activity, and neighbouring β-cells tend to act as a unit and a syncytium.
In contrast, α-cells are not coupled. ]. 68 A potential explanation for this effect considers the heterogeneity of Ca 2+ channel expression, and also may depend on specific association of certain Ca 2+ channels to secretory granules.
In addition to Ca 2+ , there are other pathways that contribute to α-cell heterogeneity. Cyclic AMP (cAMP) has been demonstrated to be a key regulator of glucagon secretion, 69 and its activity within the α-cell is connected to Ca
2+
. We and others have been developing
FRET sensors that detect cAMP responses to changes in extracellular glucose. 70 Another important experimental advance is a new glucagon knock-in Cre mouse, which labels >95% of the α-cells. Lastly, we anticipate that the high throughput and the high sensitivity of single-cell in situ hybridization and RNA-sequencing methods will soon reveal heterogeneity in the α-cell transcriptome, as they have done for the β-cell field. [74] [75] [76] The identification of differential expression of transcription factors, signalling receptors, and perhaps diabetes-related genes within different α-cell subtypes, will likely reveal novel pathways and targets for therapeutic intervention.
| cAMP AS REGULATOR OF GLUCAGON
The second messenger cyclic adenosine monophosphate (cAMP) was first identified as a critical element of the liver response to glucagon signalling. 77 The specific role of ACs in α-cell is yet to be elucidated, but we can speculate that distinct AC isoforms may be specifically linked to glucagon secretion.
The concentration of cAMP is not exclusively regulated by its synthesis rate. An equally relevant role is played by its degradation.
The phosphodiesterase (PDE) enzymes convert cAMP into 5 0 -adenosine monophosphate (5 0 -AMP). As for ACs, PDEs are expressed in many isoform, with 11 known gene families (PDE1 to PDE11) with a total of 21 gene products and 100 mRNA products. 97 The PDE families differ in their affinity and specificity for their substrate cAMP and cGMP, mechanisms of regulation, cellular expression and subcellular distribution allowing them to selectively regulate many cellular functions. Rodent islets express PDE1C, PDE3B, PDE4 and PDE10A, with PDE3B being the dominant isoform in regulating insulin secretion from β-cells. 98 Data from human islets show that PDE1, PDE3, PDE4C, PDE7A, PDE8A and PDE10A are present in islets. 99 Again there are no studies specifically addressing PDE expression and distribution in α-cells, but there is evidence of PDE3B playing a role in inhibition of glucagon secretion. 69 RNA-Seq of sorted human α-cells detects both PDE3 and PDE4. 100 It is likely that more roles for PDE in α-cells will be discovered as the effort to understand the regulation of glucagon secretion continues. Traditional biochemical methods are impractical for studying subcellular interactions due to a lack of abundant α-cell-specific starting material. Electrophysiology and immunocytochemistry can give us α-cell-specific information, but the former can only investigate channel-associated phenomena, while the latter lacks the possibility to interrogate dynamics at the timescale of secretion events. With recent improvements of genetically encoded biosensors for multiple intracellular components, greater availability of floxed reporter mice and promoter-specific CRE driver mice, and technical advances in confocal and light sheet microscopes, we finally have the necessary tools to test the many hypotheses regarding α-cell activation and secretion.
| α-CELL CONNECTIVITY
Hormone secretion is a multicellular event. As such, the mode of them GPCRs. [127] [128] [129] Moreover, they contain local cAMP and protein kinase activity that are linked to Ca 2+ dynamics. 130 Primary cilia have been implicated in the control of diverse cellular processes during development and in tissue homeostasis. While cilia are found in islet endocrine and exocrine cells, [131] [132] [133] [134] [135] we know little about their role in islet function. Disruption of cilia leads to impaired first phase insulin secretion from β-cells, and diabetes in rodents is associated with decreased number of ciliated β-cells. 135 We and others have demonstrated the presence of cilia in α-cells, though their function remains to be studied. Given the signalling capacity of cilia, they may be involved in shaping α-cell connectivity, activating forward and reverse signalling between α-cells and other islet cell types, as well as cell cycle regulation, adding another dimension to the function of α-cells.
| CONCLUSION
Since no single mechanism to-date has been able to explain α-cell function during GIGS, we propose a new type of model where FIGURE 2 Isolated islets from a 27-year-old non-diabetic human donor. A, Tight junctions (arrows) between an α-and β-cell. B, Multihormonal cell containing α-cell granules (arrows), β-cell granules (arrowheads), and δ-cell granules (*). Scale bar = 1 μm multiple signalling pathways function in parallel, including paracrine, juxtacrine and α-cell intrinsic pathways working in concert to mediate GIGS. While these pathways function independently, cross-talk between them is also possible. The basics of our proposed model are that at low glucose levels glucose metabolism drives Ca 2+ influx into the α-cells, which stimulates glucagon secretion. 22, 24 Since the α-cells
are not coupled, heterogeneities in glucose metabolism and membrane excitability likely lead to the observed heterogeneous response in Ca 2+ signalling. This would be expected to lead to heterogeneous secretion among the α-cells, but this hypothesis remains untested.
As glucose levels increase, SST release from δ-cells increases, followed by increased secretion of insulin and other compounds (ie, Zn 2+ , serotonin, GABA) from the β-cells). 20 The resulting paracrine signals from these compounds reduce cAMP levels and PKA activity in the α-cells, which leads to inhibited glucagon exocytosis even in the presence of continued Ca 2+ activity. 23, 69 Since glucagon secretion never drops to zero, we hypothesize that lower PKA activity lowers the rate Studying individual signalling components both in isolation and in combination will allow us to determine how these pathways combine synergistically to produce the robust GIGS behaviour seen in vivo and in isolated islets. Ultimately, deeper understanding of α-cell signalling will reveal new pharmacological targets for regulating glucagon secretion and lead to novel treatments for diabetes.
